Bioluminescence Ventures

Bioluminescence Ventures is a US biotechnology venture capital firm headquartered in San Francisco. The firm invests in companies with transformational platform technologies that are developing first-in-class or best-in-class therapeutics programs. Their focus areas include breakthrough biology, drug discovery platforms, genetic medicines platforms, and computational biology platforms.

The firm's investment strategy centers on supporting mission-driven leaders to develop therapies for patients with major unmet medical needs. They aim to finance breakthrough platforms and support leaders in developing first-in-class or best-in-class therapies, especially during challenging financing environments. Bioluminescence Ventures prefers to lead investment rounds, working closely with a company's leadership team to complete due diligence, negotiate terms, secure syndicates, and close rounds efficiently.

Bioluminescence Ventures emerged from stealth in November 2023 with $477 million in assets under management across two funds. The firm has invested in multiple U.S. biotech companies, including Ensoma, Nido Biosciences, ReCode Therapeutics, and SURGE Therapeutics. The team is led by Founding and Managing Partner Kouki Harasaki, Ph.D., MBA, who has over 20 years of experience in biomedical science, biopharmaceuticals, technology, and venture capital. The firm is supported by an investor base that includes U.S. and multinational institutional limited partners.